Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial.

Abstract

PURPOSE:

Addition of adjuvant capecitabine improves overall survival for patients with breast cancer lacking pathologic complete response to standard-of-care neoadjuvant chemotherapy. Combining radiosensitizing capecitabine concurrent with radiation may further improve disease control, although the feasibility and tolerability of chemoradiation in this setting is unknown. This study aimed to determine the feasibility of this combination. Secondary objectives included the effect of chemoradiation on physician-reported toxicity, patient-reported skin dermatitis, and patient-reported quality of life compared with patients with breast cancer treated with adjuvant radiation.

METHODS AND MATERIALS:

Twenty patients with residual disease following standard neoadjuvant chemotherapy were enrolled in a prospective single-arm trial and treated with adjuvant capecitabine-based chemoradiation. Feasibility was defined as ≥75% of patients completing chemoradiation as planned. Toxicity was assessed using Common Terminology Criteria for Adverse Events version 5.0 and the patient-reported radiation-induced skin reaction scale. Quality of life was measured using the RAND Short-Form 36-Item Health Survey.

RESULTS:

Eighteen patients (90%) completed chemoradiation without interruption or dose reduction. The incidence of grade ≥3 radiation dermatitis was 5% (1 of 20 patients). Patient-reported radiation dermatitis did not show a clinically meaningful difference following chemoradiation (mean increase, 55 points) compared with published reports of patients with breast cancer treated with adjuvant radiation alone (mean increase, 47 points). On the other hand, patient-reported quality of life demonstrated a clinically meaningful decline at the end of chemoradiation (mean, 46; SD, 7) compared with the reference population of patients treated with adjuvant radiation alone (mean, 50; SD, 6).

CONCLUSIONS:

Adjuvant chemoradiation with capecitabine is feasible and tolerable in patients with breast cancer. Although current studies using adjuvant capecitabine for residual disease following neoadjuvant chemotherapy have specified sequential treatment of capecitabine and radiation, these results support the conduct of randomized trials in this setting to investigate the efficacy of concurrent radiation with capecitabine and provide patient-reported toxicity estimates for trial design.

• Authors: Meridith L Balbach, Alexander D Sherry, Brent N Rexer, Vandana G Abramson, Kenneth J Niermann, Corbin R Johnson, Ben Ho Park, Ingrid A Mayer, A Bapsi Chakravarthy
• Journal: International journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 118 Issue 5 Pg. 1262-1270 (Apr 01 2024) ISSN: 1879-355X [Electronic] United States
• PMID: 37433376 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 Elsevier Inc. All rights reserved.

Chemical References

• Capecitabine
• Fluorouracil

Topics

• Humans
• Female
• Capecitabine
• Breast Neoplasms (drug therapy, radiotherapy)
• Neoadjuvant Therapy (adverse effects, methods)
• Quality of Life
• Feasibility Studies
• Prospective Studies
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Chemoradiotherapy, Adjuvant
• Dermatitis
• Chemotherapy, Adjuvant (adverse effects, methods)
• Fluorouracil
• Rectal Neoplasms (pathology)